Pulmonary embolism occurred within 3 weeks after initiation of tirzepatide 2.5 mg weekly in a 35-year-old obese woman with underlying prothrombin G20210A mutation and obesity.
Case Report (n=1)
No
35-year-old obese woman (BMI 42 kg/m2) with pulmonary embolism following tirzepatide initiation and heterozygosity for prothrombin G20210A mutation (n=1)
Tirzepatide (2.5 mg weekly)
Occurrence of pulmonary embolism (PE)
Building similarity graph...
Analyzing shared references across papers
Loading...
Muhammad Aleem
Hassan Ur Rehman
Khyber Teaching Hospital
Building similarity graph...
Analyzing shared references across papers
Loading...
Aleem et al. (Sun,) conducted a case report in 35-year-old obese woman (BMI 42 kg/m2) with pulmonary embolism following tirzepatide initiation and heterozygosity for prothrombin G20210A mutation (n=1). Tirzepatide was evaluated on Occurrence of pulmonary embolism (PE). Pulmonary embolism occurred within 3 weeks after initiation of tirzepatide 2.5 mg weekly in a 35-year-old obese woman with underlying prothrombin G20210A mutation and obesity.
synapsesocial.com/papers/69a761bdc6e9836116a2fcd2 — DOI: https://doi.org/10.1016/j.aed.2026.02.005